Systematic monitoring for autoimmunity in inflammatory rheumatism patients receiving anti-TNF therapy reported rates of 20-60% for ANA, 15-20% for anti-DNA, and 15-20% for anti-histones [14-18]. Here, BTG3 is linked to rheumatic disorder.